54 results match your criteria feasible radiosensitizing

Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial).

Radiother Oncol 2021 07 5;160:159-165. Epub 2021 May 5.

Radiotherapy Department, Grenoble Alps University Hospital, Grenoble, France.

Background And Purpose: Brain metastasis impacts greatly on patients' quality of life and survival. The phase I NANO-RAD trial assessed the safety and maximum tolerated dose of systemic administration of a novel gadolinium-based nanoparticle, AGuIX, in combination with whole brain radiotherapy in patients with multiple brain metastases not suitable for stereotactic radiotherapy.

Materials And Methods: Patients with measurable brain metastases received escalating doses of AGuIX nanoparticles (15, 30, 50, 75, or 100 mg/kg intravenously) on the day of initiation of WBRT (30 Gy in 10 fractions) in 5 cohorts of 3 patients each. Read More

View Article and Full-Text PDF

Tumor-targeted pH-low insertion peptide delivery of theranostic gadolinium nanoparticles for image-guided nanoparticle-enhanced radiation therapy.

Transl Oncol 2020 Nov 4;13(11):100839. Epub 2020 Aug 4.

Department of Therapeutic Radiology, Yale University, School of Medicine, New Haven, CT, USA.

Tumor targeting studies using metallic nanoparticles (NPs) have shown that the enhanced permeability and retention effect may not be sufficient to deliver the amount of intratumoral and intracellular NPs needed for effective in vivo radiosensitization. This work describes a pH-Low Insertion Peptide (pHLIP) targeted theranostic agent to enable image-guided NP-enhanced radiotherapy using a clinically feasible amount of injected NPs. Conventional gadolinium (Gd) NPs were conjugated to pHLIPs and evaluated in vitro for radiosensitivity and in vivo for mouse MRI. Read More

View Article and Full-Text PDF
November 2020

Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.

Urol Oncol 2020 11 27;38(11):848.e9-848.e16. Epub 2020 Jun 27.

Department of Urology, Weill Cornell Medicine, New York, NY; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, NewYork Presbyterian Hospital, New York, NY. Electronic address:

Background: Docetaxel remains a standard of care for metatsatic castration resistant porstate cancer (mCRPC) and has radiosensitizing properties. The dose limiting toxicity (DLT) of radioimmunotherapy is myelosuppression; dose fractionation of Lu-J591 allows similar administered doses with less toxicity. This study (NCT00916123) was designed to determine the safety, DLT, and maximum tolerated dose of fractionated Lu-J591 administered concurrently with standard docetaxel. Read More

View Article and Full-Text PDF
November 2020

Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [Cu]Cu-NOTA-panitumumab F(ab') alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib.

Nucl Med Biol 2020 May - Jun;84-85:46-54. Epub 2020 Feb 3.

Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada; Department of Medical Imaging, University of Toronto, Toronto, ON, Canada; Toronto General Research Institute, Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada. Electronic address:

Introduction: Our objective was to determine the feasibility of extending our previously reported PET imaging study of pancreatic cancer (PnCa) with [Cu]Cu-NOTA-panitumumab F(ab') to radioimmunotherapy (RIT) by exploiting the β-particle and Auger electron emissions of Cu (PET theranostic concept). To enhance the effectiveness of [Cu]Cu-NOTA-panitumumab F(ab'), we further combined RIT with radiosensitizing gemcitabine (GEM) and the poly(ADP)ribose polymerase inhibitor (PARPi), rucaparib.

Methods: Normal tissue toxicity was assessed in non-tumor-bearing NOD-scid mice injected i. Read More

View Article and Full-Text PDF

Modulation of nanoparticle uptake, intracellular distribution, and retention with docetaxel to enhance radiotherapy.

Br J Radiol 2020 Feb 12;93(1106):20190742. Epub 2019 Dec 12.

Department of Physics and Astronomy, University of Victoria, Victoria, BC, Canada.

Objective: One of the major issues in current radiotherapy (RT) is the normal tissue toxicity. A smart combination of agents within the tumor would allow lowering the RT dose required while minimizing the damage to healthy tissue surrounding the tumor. We chose gold nanoparticles (GNPs) and docetaxel (DTX) as our choice of two radiosensitizing agents. Read More

View Article and Full-Text PDF
February 2020

The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.

Int J Oncol 2019 Dec 30;55(6):1287-1295. Epub 2019 Sep 30.

Department of Immunology, Genetics and Pathology, Uppsala University, 751 87 Uppsala, Sweden.

177Lu‑DOTATATE was recently approved for the treatment of somatostatin receptor (SSTR)‑positive neuroendocrine tumors (NETs). However, despite impressive response rates, complete responses are rare. Heat shock protein 90 (HSP90) inhibitors have been suggested as suitable therapeutic agents for NETs, as well as a potential radiosensitizers. Read More

View Article and Full-Text PDF
December 2019

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation.

Oncotarget 2019 Sep 3;10(51):5372-5382. Epub 2019 Sep 3.

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

There is a need for preclinical models that can enable identification of novel radiosensitizing drugs in clinically relevant high-throughput experiments. We used a new high-throughput compatible total cell kill spheroid assay to study the interaction between drugs and radiation in order to identify compounds with radiosensitizing activity. Experimental drugs were compared to known radiosensitizers and cytotoxic drugs clinically used in combination with radiotherapy. Read More

View Article and Full-Text PDF
September 2019

Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.

Radiother Oncol 2019 03 20;132:55-62. Epub 2018 Dec 20.

Department of Internal Medicine, Division of Hematology Oncology, University of Nebraska Medical Center, Omaha, USA.

Introduction: The HIV protease inhibitor nelfinavir (NFV) displays notable radiosensitizing effects. There have been no studies evaluating combined stereotactic body radiotherapy (SBRT) and NFV for borderline/unresectable pancreatic cancer. The primary objective of this phase I trial (NCT01068327) was to determine the maximum tolerated SBRT/NFV dose, and secondarily evaluate outcomes. Read More

View Article and Full-Text PDF

Re‑irradiation plus hyperthermia for recurrent pediatric sarcoma; a simulation study to investigate feasibility.

Int J Oncol 2019 Jan 2;54(1):209-218. Epub 2018 Nov 2.

Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Recurrent pediatric tumors pose a challenge since treatment options may be limited, particularly after previous irradiation. Positive results have been reported for chemotherapy and hyperthermia, but the combination of re‑irradiation and hyperthermia has not been investigated thus far, although it is a proven treatment strategy in adults. The theoretical feasibility of re‑irradiation plus hyperthermia was investigated for infield recurrent pediatric sarcoma in the pelvic region and the extremities. Read More

View Article and Full-Text PDF
January 2019

Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.

Chin J Cancer 2016 12 22;35(1):101. Epub 2016 Dec 22.

Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, 200321, P. R. China.

Background: After definitive chemoradiotherapy for non-metastatic nasopharyngeal carcinoma (NPC), more than 10% of patients will experience a local recurrence. Salvage treatments present significant challenges for locally recurrent NPC. Surgery, stereotactic ablative body radiotherapy, and brachytherapy have been used to treat locally recurrent NPC. Read More

View Article and Full-Text PDF
December 2016

Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer.

Onco Targets Ther 2016 19;9:2359-64. Epub 2016 Apr 19.

Medical Oncology Unit, San Giuseppe Moscati Hospital, Taranto, Italy.

Background: Concurrent chemoradiotherapy (CCRT) using cisplatin-based doublets represents the standard of care for locally advanced non-small cell lung cancer (NSCLC), having shown good efficacy and activity in clinical trials. Locally advanced NSCLC occurs frequently in the elderly population, which is often excluded by platinum-based CCRT administration, due to severe associated toxicities. This limitation has been overcome using new-generation drugs such as gemcitabine, docetaxel, paclitaxel, and vinorelbine, which have shown not only to be efficacious but also to have a favorable toxicity spectrum, both in association with cisplatin and as single agents. Read More

View Article and Full-Text PDF

Targeted radiotherapy enhancement during electronic brachytherapy of accelerated partial breast irradiation (APBI) using controlled release of gold nanoparticles.

Phys Med 2015 Dec 26;31(8):1070-1074. Epub 2015 Sep 26.

Medical Physics Program, Department of Physics and Applied Physics, University of Massachusetts at Lowell, 1 University Ave., Olney Science Center, Lowell, MA 01854, USA; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Jimmy Fund Building, Boston, MA 02215, USA.

Several studies have demonstrated low rates of local recurrence with brachytherapy-based accelerated partial breast irradiation (APBI). However, long-term outcomes on toxicity (e.g. Read More

View Article and Full-Text PDF
December 2015

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.

BMC Cancer 2015 Mar 3;15:89. Epub 2015 Mar 3.

Medical Science Research Institute, Seoul National University Bundang Hospital, Seongnam, Korea.

Background: Triple-negative breast cancer (TNBC) shows aggressive clinical behavior, but the treatment options are limited due to lack of a specific target. TNBC shares many clinical and pathological similarities with BRCA-deficient breast cancer, for which poly(ADP-ribose) polymerase (PARP) inhibitor is effective, but PARP inhibitor alone failed to show clinical effects in patients with sporadic TNBC. Radiation induces DNA double-strand breaks, and the phosphoinositide 3-kinase (PI3K) signaling pathway has been known to regulate steady-state levels of homologous recombination. Read More

View Article and Full-Text PDF

Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.

Target Oncol 2015 Sep 11;10(3):375-83. Epub 2014 Oct 11.

Institut de Recherche Expérimentale et Clinique, Pôle d'imagerie médicale, radiothérapie et oncologie (IREC/MIRO), Université catholique de Louvain, Brussels, Belgium.

Our goal was to optimize the radiosensitizing potential of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, when given concomitantly with preoperative radiotherapy in KRAS wild-type locally advanced rectal cancer (LARC). Based on pre-clinical studies conducted by our group, we designed a phase II trial in which panitumumab (6 mg/kg/q2 weeks) was combined with preoperative radiotherapy (45 Gy in 25 fractions) to treat cT3-4/N + KRAS wild-type LARC. The primary endpoint was complete pathologic response (pCR) (H0 = 5%, H1 = 17%, α = 0. Read More

View Article and Full-Text PDF
September 2015

Suppression of autophagy augments the radiosensitizing effects of STAT3 inhibition on human glioma cells.

Exp Cell Res 2015 Jan 16;330(2):267-276. Epub 2014 Sep 16.

Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Suzhou 215123, China. Electronic address:

Radiotherapy is an essential component of the standard therapy for newly diagnosed glioblastoma. To increase the radiosensitivity of glioma cells is a feasible solution to improve the therapeutic effects. It has been suggested that inhibition of signal transducer and activator of transcription 3 (STAT3) can radiosensitize glioma cells, probably via the activation of mitochondrial apoptotic pathway. Read More

View Article and Full-Text PDF
January 2015

Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro.

Radiat Oncol 2013 Nov 6;8:260. Epub 2013 Nov 6.

Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, Heidelberg 69120, Germany.

Background: Characterization of combination effects of chemotherapy drugs with carbon ions in comparison to photons in vitro.

Methods: The human colon adenocarcinoma cell line WiDr was tested for combinations with camptothecin, cisplatin, gemcitabine and paclitaxel. In addition three other human tumour cell lines (A549: lung, LN-229: glioblastoma, PANC-1: pancreas) were tested for the combination with camptothecin. Read More

View Article and Full-Text PDF
November 2013

Electron-induced degradation of 8-bromo-2'-deoxyadenosine 3',5'-diphosphate, a DNA radiosensitizing nucleotide.

J Phys Chem B 2013 Jul 10;117(29):8681-8. Epub 2013 Jul 10.

Department of Chemistry, University of Gdańsk, Sobieskiego 18, 80-952 Gdańsk, Poland.

The phosphodiester bond cleavage in 8-bromo-2'-deoxyadenosine 3',5'-diphosphate (BrdADP), as a model of electron induced single strand break (SSB) in labeled DNA, was investigated at the B3LYP/6-31++G(d,p) level of theory both in the gas phase and in water solution. Barrier-free and highly exergonic, especially in water solution (-2.83 eV), release of the bromide anion due to electron attachment confirms radiosensitizing properties of 8-bromoadenine. Read More

View Article and Full-Text PDF

Current status of radiosensitizing agents for the management of rectal cancer.

Henrik Illum

Crit Rev Oncog 2012 ;17(4):345-59

Department of Hematology Oncology, Assistant Professor of Medicine, University of Texas Southwestern, 4500 S. Lancaster Road, Dallas, TX 75216, USA.

The management of locally advanced rectal cancer requires a multidisciplinary effort. Surgical resection remains the therapeutic cornerstone, but neoadjuvant chemoradiation clearly improves both surgical and long-term outcomes. Pathological complete response is a desirable outcome and has been associated with good long-term outcomes. Read More

View Article and Full-Text PDF
February 2013

Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy.

Cancer Gene Ther 2012 Oct 3;19(10):697-706. Epub 2012 Aug 3.

Department of Respiratory Medicine, the First Hospital Affiliated to Soochow University, Suzhou, China.

Radiotherapy is the common treatment of choice for locally advanced lung cancer, but the radioresistance of lung cancer remains a significant therapeutic obstacle. We previously demonstrated that adenovirus-mediated inhibitor of growth 4 (ING4) tumor suppressor gene delivery (AdVING4) can chemosensitize human hepatocarcinoma cells to anticancer drug cisplatin (CDDP). However, its radiosensitizing effects in cancer therapy are largely elusive. Read More

View Article and Full-Text PDF
October 2012

Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology.

Ann Nucl Med 2012 May 25;26(4):365-9. Epub 2012 Feb 25.

THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, 99437, Bad Berka, Germany.

Few studies have been published on the safety and feasibility of synchronous use of peptide receptor radionuclide therapy (PRRNT), as source of internal radiation therapy, in combination with chemotherapy. In this study we reported a 53-year-old man with stage IV Merkel cell carcinoma (MCC), who underwent synchronous internal radiation therapy and chemotherapy. Based on presumable poor prognosis with chemotherapy only, functional similarities of MCC with other neuroendocrine tumors and available evidence of effectiveness and safety of synchronous use of external beam radiation therapy and chemotherapy in treatment of high-risk MCC patients, our interdisciplinary neuroendocrine tumor board recommended him to add PRRNT to his ongoing chemotherapy. Read More

View Article and Full-Text PDF

A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer.

Radiat Oncol 2012 Jan 11;7. Epub 2012 Jan 11.

Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway.

Treatment of non-small cell lung cancer (NSCLC) is challenging in many ways. One of the problems is disappointing local control rates in larger volume disease. Moreover, the likelihood of both nodal and distant spread increases with primary tumour (T-) stage. Read More

View Article and Full-Text PDF
January 2012

Reirradiation in head and neck cancers.

Anticancer Drugs 2011 Aug;22(7):634-8

Department of Head and Neck Surgery, Institut Gustave Roussy, Villejuif, France.

Salvage surgery is the mainstay of treatment for recurrences or secondary primary tumors in areas that were irradiated earlier. However, locoregional recurrence remains the main cause of death after surgery. Adjuvant reirradiation dramatically reduces locoregional recurrences but the risk-benefit ratio seems to be advantageous mostly for residual microscopic disease. Read More

View Article and Full-Text PDF

Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.

Cancer 2011 Jul 18;117(14):3173-81. Epub 2011 Jan 18.

Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York, USA.

Background: Concurrent inhibition of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) is an active and well tolerated regimen in recurrent head and neck cancer (HNC). In the current phase 1 trial, the authors sought to determine the maximum tolerated dose (MTD) and efficacy of concurrent erlotinib and celecoxib as a radiosensitizing regimen.

Methods: Fourteen patients with previously irradiated HNC with no distant metastases who required reirradiation were eligible. Read More

View Article and Full-Text PDF

Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.

Thyroid 2011 Jan 16;21(1):25-30. Epub 2010 Dec 16.

Endocrine Malignancies Disease Oriented Group, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA.

Background: Historical outcomes in anaplastic thyroid carcinoma (ATC) are poor, with a median survival of only 5 months and <20% of patients surviving 1 year from diagnosis. We hypothesized that survival in newly diagnosed patients with stages IVA and IVB locoregionally confined ATC might be improved by utilizing an aggressive therapeutic approach, prioritizing both the eradication of disease in the neck and preemptive treatment of occult metastatic disease.

Methods: Between January 1, 2003, and December 31, 2007, 25 new ATC patients were evaluated at our institution. Read More

View Article and Full-Text PDF
January 2011

A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.

J Thorac Oncol 2010 Jan;5(1):69-74

Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27516, USA.

Background: Concurrent radiation and chemotherapy is the standard of care for good performance status patients with stage III non-small cell lung cancer. Locoregional control remains a significant factor relating to poor outcome. Preclinical and early clinical data suggest that docetaxel and gefitinib have radiosensitizing activity. Read More

View Article and Full-Text PDF
January 2010

Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.

Clin Cancer Res 2009 Nov 3;15(22):7069-76. Epub 2009 Nov 3.

Departments of Pathology, and Radiotherapy/Oncology, Democritus University of Thrace, Alexandroupolis, Greece.

Purpose: Anti-vascular endothelial growth factor therapy enhances the activity of radiotherapy in experimental models, and bevacizumab has therapeutic activity in patients with metastatic colorectal cancer.

Experimental Design: Twenty-two patients with locally advanced inoperable colorectal carcinomas (LA/I-CRC) were treated with conformal hypofractionated (3.4 Gy/fraction x 15) split-course accelerated radiotherapy (biological equivalent dose, 67. Read More

View Article and Full-Text PDF
November 2009

Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.

Int J Radiat Oncol Biol Phys 2010 Mar 27;76(4):998-1004. Epub 2009 Jun 27.

Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Purpose: Trastuzumab (Herceptin), an anti-human epidermal growth factor receptor 2 (HER2) antibody, has been shown to be an effective radiosensitizer in preclinical studies. The present Phase II trial evaluated trastuzumab plus radiotherapy in patients with HER2-positive, chemotherapy-refractory, locally advanced or locoregionally recurrent breast cancer.

Methods And Materials: Eligible patients had measurable disease, normal cardiac function, and biopsy-confirmed residual HER2-positive disease. Read More

View Article and Full-Text PDF

Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.

Int J Radiat Oncol Biol Phys 2007 Nov;69(4):1246-53

Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.

Purpose: To investigate the radiosensitizing potential of temozolomide (TMZ) for human glioblastoma multiforme (GBM) cell lines using single-dose and fractionated gamma-irradiation.

Methods And Materials: Three genetically characterized human GBM cell lines (AMC-3046, VU-109, and VU-122) were exposed to various single (0-6 Gy) and daily fractionated doses (2 Gy per fraction) of gamma-irradiation. Repeated TMZ doses were given before and concurrent with irradiation treatment. Read More

View Article and Full-Text PDF
November 2007

Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer.

Clin Lung Cancer 2006 Sep;8(2):122-9

Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

Background: The optimal treatment of locally advanced non-small-cell lung cancer remains a challenge. Although the benefit of combined chemoradiation has been established, the optimal chemotherapy regimen, timing of full-dose chemotherapy, and how best to combine chemotherapy with radiation to maximize systemic and radiosensitizing effects remain unclear.

Patients And Methods: Twenty-nine patients with pathologically confirmed stage IIIA/IIIB non-small-cell lung cancer were included in a phase II trial of sequential carboplatin/paclitaxel followed by chemoradiation, surgery, and postoperative gemcitabine. Read More

View Article and Full-Text PDF
September 2006

Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.

Mol Cancer Ther 2006 Feb;5(2):411-7

Department of Radiation Oncology, B-902, The Vanderbilt Clinic, Vanderbilt University, 1301 22nd Avenue South, Nashville, TN 37232-5671, USA.

p53 plays a critical role in cell cycle arrest and induction of apoptosis. Certain malignancies carry wild-type p53, which is frequently down-regulated by murine double minute 2 (MDM2) overexpression. Availability of a small-molecule inhibitor against MDM2, nutlin, has made it feasible to evaluate the anti-MDM2-based therapeutic strategies. Read More

View Article and Full-Text PDF
February 2006